Anti-tumor agents

• US 20060287245A1
• Filed: 06/28/2006
• Published: 12/21/2006
• Est. Priority Date: 05/25/1999
• Status: Active Grant

• Current Assignee: DARA Biosciences Incorporated (Barings LLC (Private Equity))
• Original Assignee: Point Therapeutics, Inc. (Barings LLC (Private Equity))
• Inventors: Miller, Glenn, Wallner, Barbara
• Granted Patent: US 7,282,484 B2
• Time in Patent Office: Days
• US Class Current: 514/19.400
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

Claims

1-37. -37. (canceled)

38. A method for treating a subject having cancer, comprising:

administering to a subject in need of such treatment, an agent in an amount effective to inhibit the proliferation, wherein the agent is

wherein each D₁ and D₂, independently, is a hydroxyl group or a group which is capable of being hydrolysed to a hydroxyl group in aqueous solution at physiological pH, and X is an amino acid having an amino terminal amino group with an N-terminal blocking group at the amino terminal amino group, and wherein the cancer is carcinoma, sarcoma or melanoma.

39. The method of claim 38, wherein the N-terminal blocking group is

40. The method of claim 38, wherein the cancer is lung cancer.

41. The method of claim 40, wherein the cancer is giant cell carcinoma, squamous cell carcinoma or adenocarcinoma.

42. The method of claim 38, wherein the cancer is pancreatic cancer.

43. The method of claim 38, wherein the cancer is kidney cancer.

44. The method of claim 38, wherein the cancer is breast cancer or colorectal cancer.

45. The method of claim 38, wherein the cancer is fibrosarcoma, osteosarcoma, or liposarcoma.

46. The method of claim 38, wherein the cancer is melanoma.

47. The method of claim 38-46, wherein the agent is administered orally.

48. The method of claim 47, further comprising administering to the subject an anti-cancer compound.

49. The method of claim 38-46, further comprising administering to the subject an anti-cancer compound.